{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:39Z","timestamp":1793296119729,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-03022-z","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:27:24Z","timestamp":1767025644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD\u00ae) reported to the vaccine adverse event reporting system (VAERS), 2015\u20132025"],"prefix":"10.1186","volume":"22","author":[{"given":"Guojun","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"12","key":"3022_CR1","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1080\/21645515.2021.2007710","volume":"17","author":"BJ Kuter","year":"2021","unstructured":"Kuter BJ, Marshall GS, Fergie J, Schmidt E, Pawaskar M. Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R(II). Hum Vaccin Immunother. 2021;17(12):5372\u201383.","journal-title":"Hum Vaccin Immunother"},{"key":"3022_CR2","doi-asserted-by":"publisher","unstructured":"Minta AA, Ferrari M, Antoni S, et al. Progress toward regional measles elimination - worldwide, 2000\u20132021. MMWR Morb Mortal Wkly Rep. 2022;71(47):1489\u201395. https:\/\/doi.org\/10.15585\/mmwr.mm7147a1.","DOI":"10.15585\/mmwr.mm7147a1"},{"key":"3022_CR3","doi-asserted-by":"publisher","unstructured":"Ximmerman LA, Knapp JK, Antoni S, Grant GB, Reef SE. Progress toward rubella and congenital rubella syndrome control and elimination - worldwide, 2012\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71(6):196\u2013201. https:\/\/doi.org\/10.15585\/mmwr.mm7106a2.","DOI":"10.15585\/mmwr.mm7106a2"},{"issue":"10","key":"3022_CR4","doi-asserted-by":"publisher","first-page":"e1412","DOI":"10.1016\/S2214-109X(22)00335-7","volume":"10","author":"AK Winter","year":"2022","unstructured":"Winter AK, Lambert B, Klein D, et al. Feasibility of measles and Rubella vaccination programmes for disease elimination: a modelling study. Lancet Global Health. 2022;10(10):e1412\u201322.","journal-title":"Lancet Global Health"},{"key":"3022_CR5","doi-asserted-by":"publisher","unstructured":"Zhou F, Leung J, Marin M, Dooling KL, Anderson TC, Ortega-Sanchez IR. Health and economic impact of the United States Varicella Vaccination Program, 1996\u20132020. J Infect Dis. 2022;226(Suppl 4):S463\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiac271.","DOI":"10.1093\/infdis\/jiac271"},{"key":"3022_CR6","doi-asserted-by":"publisher","unstructured":"Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect. 2010;138(4):469\u201381. https:\/\/doi.org\/10.1017\/S0950268809990768.","DOI":"10.1017\/S0950268809990768"},{"issue":"1","key":"3022_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1542\/peds.2010-0665","volume":"126","author":"NP Klein","year":"2010","unstructured":"Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1\u20138.","journal-title":"Pediatrics"},{"issue":"48","key":"3022_CR8","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1016\/j.vaccine.2012.08.075","volume":"30","author":"ST O\u2019Leary","year":"2012","unstructured":"O\u2019Leary ST, Suh CA, Marin M. Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think? Vaccine. 2012;30(48):6731\u20133.","journal-title":"Vaccine"},{"issue":"52","key":"3022_CR9","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1016\/j.vaccine.2014.08.067","volume":"32","author":"SO Klopfer","year":"2014","unstructured":"Klopfer SO, Stek JE, Petrecz M, et al. Analysis of safety data in children after receiving two doses of ProQuad(R) (MMRV). Vaccine. 2014;32(52):7154\u201360.","journal-title":"Vaccine"},{"issue":"RR\u20133","key":"3022_CR10","first-page":"1","volume":"59","author":"M Marin","year":"2010","unstructured":"Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59(RR\u20133):1\u201312.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"3022_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1542\/peds.2011-3198","volume":"129","author":"NP Klein","year":"2012","unstructured":"Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809\u201314.","journal-title":"Pediatrics"},{"issue":"1","key":"3022_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/14760584.2023.2252065","volume":"22","author":"G Casabona","year":"2023","unstructured":"Casabona G, Berton O, Singh T, Knuf M, Bonanni P. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context. Expert Rev Vaccines. 2023;22(1):764\u201376.","journal-title":"Expert Rev Vaccines"},{"key":"3022_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050456","author":"P Stefanizzi","year":"2021","unstructured":"Stefanizzi P, De Nitto S, Spinelli G, et al. Post-marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an Italian prospective observational study. Vaccines (Basel). 2021;9(5):456. https:\/\/doi.org\/10.3390\/vaccines9050456.","journal-title":"Vaccines"},{"key":"3022_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2024.100485","volume":"18","author":"PA ShamaeiZadeh","year":"2024","unstructured":"ShamaeiZadeh PA, Jaimes CV, Knoll MD, Espi\u00e9 E, Chandler RE. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally. Vaccine X. 2024;18:100485.","journal-title":"Vaccine X"},{"issue":"36","key":"3022_CR15","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398\u2013405.","journal-title":"Vaccine"},{"issue":"2","key":"3022_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"2","key":"3022_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.therap.2018.10.006","volume":"74","author":"ML Laroche","year":"2019","unstructured":"Laroche ML, Sirois C, Reeve E, Gnjidic D, Morin L. Pharmacoepidemiology in older people: purposes and future directions. Therapie. 2019;74(2):325\u201332.","journal-title":"Therapie"},{"issue":"16","key":"3022_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.46234\/ccdcw2024.066","volume":"6","author":"L Xia","year":"2024","unstructured":"Xia L, Li K, Li Y, et al. Comparison of statistical signal detection methods in adverse events following immunization - China, 2011\u20132015. China CDC Wkly. 2024;6(16):350\u20136.","journal-title":"China CDC Wkly"},{"issue":"6","key":"3022_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3022_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"3022_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159\u201386.","journal-title":"Drug Saf"},{"issue":"6","key":"3022_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"issue":"6","key":"3022_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US fda\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"key":"3022_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2020-000972","author":"KA Pohlman","year":"2020","unstructured":"Pohlman KA, Carroll L, Tsuyuki RT, Hartling L, Vohra S. Comparison of active versus passive surveillance adverse event reporting in a paediatric ambulatory chiropractic care setting: a cluster randomised controlled trial. BMJ Open Qual. 2020;9(4):e000972. https:\/\/doi.org\/10.1136\/bmjoq-2020-000972.","journal-title":"BMJ Open Qual"},{"issue":"12","key":"3022_CR25","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1016\/j.vaccine.2024.03.024","volume":"42","author":"P Stefanizzi","year":"2024","unstructured":"Stefanizzi P, Moscara L, Palmieri C, et al. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: data from active surveillance program. Puglia (Italy), 2021-23. Vaccine. 2024;42(12):2966\u201374.","journal-title":"Vaccine"},{"issue":"11","key":"3022_CR26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1503\/cmaj.140078","volume":"186","author":"SE MacDonald","year":"2014","unstructured":"MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ. 2014;186(11):824\u20139.","journal-title":"CMAJ"},{"issue":"34","key":"3022_CR27","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","volume":"27","author":"SJ Jacobsen","year":"2009","unstructured":"Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656\u201361.","journal-title":"Vaccine"},{"issue":"8","key":"3022_CR28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1080\/21645515.2019.1704124","volume":"16","author":"P Stefanizzi","year":"2020","unstructured":"Stefanizzi P, De Nitto S, Patano F. Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in Apulia region (ITALY), 2009-2017. Hum Vaccin Immunother. 2020;16(8):1875\u201383.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"3022_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164792","volume":"11","author":"J Xie","year":"2016","unstructured":"Xie J, Codd C, Mo K, He Y. Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based VAERS and literature meta-analysis. PLoS One. 2016;11(10):e0164792.","journal-title":"PLoS One"},{"issue":"Suppl 4","key":"3022_CR30","doi-asserted-by":"publisher","first-page":"S431","DOI":"10.1093\/infdis\/jiac306","volume":"226","author":"PL Moro","year":"2022","unstructured":"Moro PL, Leung J, Marquez P, et al. Safety surveillance of varicella vaccines in the vaccine adverse event reporting System, united States, 2006\u20132020. J Infect Dis. 2022;226(Suppl 4):S431\u201340.","journal-title":"J Infect Dis"},{"issue":"1","key":"3022_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1935170","volume":"18","author":"M Betancourt-Cravioto","year":"2022","unstructured":"Betancourt-Cravioto M, Cervantes-Powell P, Tapia-Conyer R, Ledlie S, Gandhi-Banga S. Improved post-marketing safety surveillance of quadrivalent inactivated influenza vaccine in Mexico using a computerized, SMS-based follow-up system. Hum Vaccin Immunother. 2022;18(1):1935170.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"3022_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.vaccine.2022.12.059","volume":"41","author":"HS Whitehead","year":"2023","unstructured":"Whitehead HS, French CE, Caldwell DM, Letley L, Mounier-Jack S. A systematic review of communication interventions for countering vaccine misinformation. Vaccine. 2023;41(5):1018\u201334.","journal-title":"Vaccine"},{"key":"3022_CR33","doi-asserted-by":"publisher","unstructured":"Cutroneo PM, Sartori D, Tuccori M, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057.","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-03022-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:27:25Z","timestamp":1767025645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-025-03022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3022"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-03022-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study performed a secondary analysis of publicly available, de-identified adverse event reports retrieved from the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance system jointly managed by the U.S. CDC and FDA. No individual-level identifiers were accessed, and no attempt was made to re-identify subjects. Because only anonymous, open-access data were used, this work does not constitute human subjects research under U.S. federal regulations and institutional policies, and thus formal Institutional Review Board review or ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the author(s) used DeepL (\n                      \n                      ) and Youdao (\n                      \n                      ) in order to improve readability. After using this tool\/service, the author(s)reviewed and edited the content as needed. The author(s) take(s) full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"400"}}